-
Global Alzheimer’s Platform Foundation Statement on FDA Accelerated Approval of Lecanemab Posted on by Taylor Disselhorst in Press Releases
-
Battling The Silent Alzheimer’s EPIDEMIC in The Black Community with Roland Martin Posted on by Taylor Disselhorst in In the News
-
GAP President John Dwyer, on Lecanemab detailed results: “There is every reason for the Alzheimer’s community to have optimism today” Posted on by Taylor Disselhorst in Press Releases
-
Medicare Alzheimer’s Coverage Policy Advancing Clinical Trial Diversity Efforts Posted on by Taylor Disselhorst in In the News
-
An Alzheimer’s Dx Comparison Study Wraps Up, Researchers Plan to Add Genomic Proteomic Profiling Posted on by Taylor Disselhorst in In the News
-
Left Out for too Long: New Alzheimer’s Research Focuses on Latinos Posted on by Taylor Disselhorst in In the News
-
First of its Kind Head-to-Head Study Comparing Leading Biomarkers for Detecting Alzheimer’s Disease Closes With Unprecedented Representation from Underrepresented Populations Posted on by Taylor Disselhorst in Press Releases
-
Statement on Roche Announcement on Gantenerumab Attributed to John Dwyer, GAP Foundation President Posted on by Taylor Disselhorst in Press Releases
-
Global Alzheimer’s Platform Foundation (GAP) Supports New Bill from U.S. Representative Vern Buchanan Posted on by Taylor Disselhorst in Press Releases
-
Global Alzheimer’s Platform Foundation (GAP) Celebrates Lecanemab’s Positive Clinical Trial Results Posted on by Taylor Disselhorst in Press Releases
